Abstract:
The present invention relates to pharmaceutical compositions for inhalation which comprise one or more bronchodilators and an inhaled corticosteroid. More particularly, the present invention relates to pharmaceutical compositions comprising olodaterol, an inhaled corticosteroid and/or an anticholinergic agent. The present invention also relates to a process for preparing the pharmaceutical composition and use thereof in the treatment and/or prevention of respiratory, inflammatory or obstructive airway disease.
Abstract translation:提供:由式(I)表示的新化合物(其中虚线表示键的存在或不存在; R 1表示取代或未取代的烷基等; R 2表示取代或未取代的烷氧基等; n表示1或2; R 3表示取代或未取代的芳族碳环基等; R 4表示氢原子等; R 5不存在等; R 6表示取代或未取代的烷基等; R 7 表示-Z7-R71等; Z7表示-NR73-CO-NR72-等; R71表示取代或未取代的芳族碳环基等; R72表示氢原子等; R73表示氢原子 等),其具有抗病毒活性,特别是HIV复制抑制活性; 以及包含该化合物的药剂,特别是抗HIV药物。
Abstract:
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
Abstract:
Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein A, X, R 1 , R 2 , R 3 and R 4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
Abstract:
The invention relates to antibacterial compounds of formula (I), wherein R 1 is H, halogen, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy; R 2 is H, halogen, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or pyrrolidin-l-yl; R 3 is H, halogen, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, vinyl or 2-methoxycarbonylvinyl or R 2 and R 3 together with the two carbon atoms which bear them form a phenyl ring; R 4 is H, halogen, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy and R5 is H, (C1-C3)alkyl or cyclopropyl, or R 4 and R 5 form together a -CH 2 CH 2 CH 2 - group; A is the divalent group -CH 2 -, -CH 2 CH 2 -, #-CH(OH)CH 2 -*, #-CH 2 N(R 6 )-* or -CH 2 NHCH 2 -, wherein # indicates the point of attachment to the optionally substituted (quinazoline-2,4-dione-3-yl)methyl residue and * represents the point of attachment to the substituted (oxazolidinon-4-yl)methyl residue; R 6 is H or acetyl; Y is CH or N; and Q is O or S; and salts of such compounds.
Abstract:
Disclosed are benzomorpholine derivatives as represented by the following formula (I) and pharmaceutical compositions comprising the derivatives as well as methods of preparation thereof, R1, R2 and R3 are as defined in the specification. The benzomorpholine derivatives of formula (I) are an inhibitor of phosphatidylinositol 3-kinases (PI3K), and have a good inhibitory effect on PI3K and on cancer cell proliferation, thereby serving as a therapeutic agent for the treatment of tumors.
Abstract:
Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (Ca SR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (Ca SR) receptors of Formula (I).
Abstract:
The present invention relates to pharmaceutical compositions for inhalation comprising glycopyrrolate, a beta2-agonist, and optionally an inhaled corticosteroid; to a process for preparing such compositions and to the use of such compositions for the prevention and/or treatment of respiratory, inflammatory or obstructive airway disease.